These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 9759617

  • 1. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates.
    Köhler M, Hellstern P, Lechler E, Uberfuhr P, Müller-Berghaus G.
    Thromb Haemost; 1998 Sep; 80(3):399-402. PubMed ID: 9759617
    [Abstract] [Full Text] [Related]

  • 2. Hepatitis risk in cardiac surgery patients receiving factor IX concentrates.
    Rossiter SJ, Miller DC, Raney AA, Oyer PE, Reitz BA, Stinson EB, Shumway NE.
    J Thorac Cardiovasc Surg; 1979 Aug; 78(2):203-7. PubMed ID: 459527
    [Abstract] [Full Text] [Related]

  • 3. Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo.
    Hedner U, Nilsson IM, Bergentz SE.
    Thromb Haemost; 1976 Apr 30; 35(2):386-95. PubMed ID: 989639
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
    Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I.
    Thromb Haemost; 2007 Oct 30; 98(4):790-7. PubMed ID: 17938803
    [Abstract] [Full Text] [Related]

  • 5. [Substitution therapy with prothrombin complex concentrates in acquired coagulation disorders].
    Fischer M.
    Wien Klin Wochenschr; 1983 Feb 04; 95(3):82-5. PubMed ID: 6858171
    [Abstract] [Full Text] [Related]

  • 6. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW, Abildgaard C, Shitanishi KT, Harrison J, Gendler S, Heldebrant CM.
    J Lab Clin Med; 1993 Mar 04; 121(3):394-405. PubMed ID: 8445288
    [Abstract] [Full Text] [Related]

  • 7. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
    McLaughlin LF, Drummond O, MacGregor IR.
    Thromb Haemost; 1992 Nov 10; 68(5):511-5. PubMed ID: 1455396
    [Abstract] [Full Text] [Related]

  • 8. Thrombogenicity of prothrombin complex concentrates.
    Köhler M.
    Thromb Res; 1999 Aug 15; 95(4 Suppl 1):S13-7. PubMed ID: 10499904
    [Abstract] [Full Text] [Related]

  • 9. Low doses of aprotinin in aortocoronary bypass surgery--advantages and disadvantages.
    Golański R, Golański J, Chizyński K, Iwaszkiewicz A, Zasłonka J, Pietrucha T, Chrul S, Watała C.
    Med Sci Monit; 2000 Aug 15; 6(4):722-8. PubMed ID: 11208399
    [Abstract] [Full Text] [Related]

  • 10. [Use and abuse of prothrombin-complex concentrates].
    Veltkamp JJ, Siewertz van Reesema DR, Boekhout-Mussert MJ.
    Ned Tijdschr Geneeskd; 1978 May 27; 122(21):766-7. PubMed ID: 652091
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C, Menart C, Attali O, Petit PY, Lienhart A, Dechavanne M, Ingerslev J.
    Blood Coagul Fibrinolysis; 1998 Mar 27; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A, Hong A, Arguello A, Echenagucia M, Boadas A, Fabbrizzi F, Minichilli F, Bosch NB.
    Haemophilia; 2005 Nov 27; 11(6):583-8. PubMed ID: 16236107
    [Abstract] [Full Text] [Related]

  • 13. Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate.
    Pabinger-Fasching I.
    Thromb Res; 2008 Nov 27; 122 Suppl 2():S19-22. PubMed ID: 18549908
    [Abstract] [Full Text] [Related]

  • 14. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E, Mannucci PM, Gringeri A, Tagariello G, Baudo F, Bauer KA, Rosenberg RD.
    Thromb Haemost; 1994 Jun 27; 71(6):737-40. PubMed ID: 7974341
    [Abstract] [Full Text] [Related]

  • 15. [Clinical use of factor IX concentrates].
    Nyman D.
    Schweiz Med Wochenschr; 1975 Sep 13; 105(37):1188-90. PubMed ID: 1215901
    [Abstract] [Full Text] [Related]

  • 16. Prothrombin complex concentrate (Beriplex P/N)-related renal and cerebral infarctions in a patient with warfarin-associated intracerebral hemorrhage.
    Lin SY, Tang SC, Shen LJ, Jeng JS.
    J Stroke Cerebrovasc Dis; 2015 Jan 13; 24(1):e15-6. PubMed ID: 25282184
    [Abstract] [Full Text] [Related]

  • 17. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E, Björkman S, Carlsson M, Lethagen S, Nilsson IM.
    Thromb Haemost; 1993 Nov 15; 70(5):768-73. PubMed ID: 8128433
    [Abstract] [Full Text] [Related]

  • 18. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology.
    Levi M, Toh CH, Thachil J, Watson HG.
    Br J Haematol; 2009 Apr 15; 145(1):24-33. PubMed ID: 19222477
    [Abstract] [Full Text] [Related]

  • 19. Massive, fatal, intracardiac thrombosis associated with prothrombin complex concentrate.
    Warren O, Simon B.
    Ann Emerg Med; 2009 Jun 15; 53(6):758-61. PubMed ID: 19181420
    [Abstract] [Full Text] [Related]

  • 20. Current management of hemophilia B.
    Roberts HR, Eberst ME.
    Hematol Oncol Clin North Am; 1993 Dec 15; 7(6):1269-80. PubMed ID: 8294316
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.